P12CDK2-AP1 is associated with tumor progression and a poor prognosis in esophageal squamous cell carcinoma

Oncology Reports

Volumn 22, Issue 1, 2009, Pages 35-39

  Hiyoshi, Yukiharu ^a   Watanabe, Masayuki ^a   Hirashima, Koutaro ^a,b   Karashima, Ryuichi ^a   Sato, Nobutaka ^a   Imamura, Yu ^a   Nagai, Youhei ^a   Yoshida, Naoya ^a   Toyama, Eiichiro ^a   Hayashi, Naoko ^a   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

CDK2AP1; Esophageal cancer; P12

Indexed keywords

P12 CYCLIN DEPENDENT KINASE 2 ASSOCIATING PROTEIN 1; TUMOR PROTEIN; UNCLASSIFIED DRUG; CDK2AP1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LESIONS AND DEFECTS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; VASCULAR TUMOR; DISEASE COURSE; ENZYMOLOGY; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; KAPLAN MEIER METHOD; LYMPHADENECTOMY; METASTASIS; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; TIME; TREATMENT OUTCOME; VEIN;

AGED; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; VEINS;

EID: 68249158574     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000403     Document Type: Article

References (24)

1. Shintani S, Ohyama H, Zhang X, et al: p12(DOC-1) is a novel cyclin-dependent kinase 2-associated protein. Mol Cell Biol 20: 6300-6307, 2000.
2. Tsuji T, Duh FM, Latif F, et al: Cloning, mapping, expression, function, and mutation analyses of the human ortholog of the hamster putative tumor suppressor gene Doc-1. J Biol Chem 273: 6704-6709, 1998.
3. Sherr CJ and McCormick F: The RB and p53 pathways in cancer. Cancer Cell 2: 103-112, 2002.
4. Matsuo K, Shintani S, Tsuji T, et al: p12(DOC-1), a growth suppressor, associates with DNA polymerase alpha/primase. FASEB J 14: 1318-1324, 2000.
5. Hu MG, Hu GF, Kim Y, et al: Role of p12(CDK2-AP1) in transforming growth factor-beta1-mediated growth suppression. Cancer Res 64: 490-499, 2004.
6. Shintani S, Mihara M, Terakado N, et al: Reduction of p12DOC-1 expression is a negative prognostic indicator in patients with surgically resected oral squamous cell carcinoma. Clin Cancer Res 7: 2776-2782, 2001.
7. Todd R, McBride J, Tsuji T, et al: Deleted in oral cancer-1 (doc-1), a novel oral tumor suppressor gene. FASEB J 9: 1362-1370, 1995.
8. Kohno Y, Patel V, Kim Y, et al: Apoptosis, proliferation and p12(doc-1) profiles in normal, dysplastic and malignant squamous epithelium of the Syrian hamster cheek pouch model. Oral Oncol 38: 274-280, 2002.
9. Yuan Z, Sotsky Kent T and Weber TK: Differential expression of DOC-1 in microsatellite-unstable human colorectal cancer. Oncogene 22: 6304-6310, 2003.
10. Sotsky Kent T, Yuan Z, Miller A and Weber TK: Deleted in oral cancer-1 expression upregulates proapoptosis elements in microsatellite-unstable human colorectal cancer. Ann Surg Oncol 11: 192-196, 2004.
11. Sobin LH and Wittekind CH (eds): International Union Against Cancer (UICC): TNM classification of malignant tumors. 6th edition. Wiley, New York, 2002.
12. Hamilton SR and Aaltonen LA: World Health Organization classification of tumours. Tumours of the Digestive System. IARC Press, Lyon, 2000.
13. Sabik JF, Rice TW, Goldblum JR, et al: Superficial esophageal carcinoma. Ann Thorac Surg 60: 896-902, 1995.
14. Rice TW, Zuccaro G Jr, Adelstein DJ, Rybicki LA, Blackstone EH and Goldblum JR: Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg 65: 787-792, 1998.
15. Tajima Y, Nakanishi Y, Ochiai A, et al: Histopathologic findings predicting lymph node metastasis and prognosis of patients with superficial esophageal carcinoma: analysis of 240 surgically resected tumors. Cancer 88: 1285-1293, 2000.
16. Matsubara T, Ueda M, Abe T, Akimori T, Kokudo N and Takahashi T: Unique distribution patterns of metastatic lymph nodes in patients with superficial carcinoma of the thoracic oesophagus. Br J Surg 86: 669-673, 1999.
17. Fujita H, Sueyoshi S, Yamana H, et al: Optimum treatment strategy for superficial esophageal cancer: endoscopic mucosal resection versus radical esophagectomy. World J Surg 25: 424-431, 2001.
18. Tachibana M, Yoshimura H, Kinugasa S, et al: Clinicopathological features of superficial squamous cell carcinoma of the esophagus. Am J Surg 174: 49-53, 1997.
19. Endo M, Yoshino K, Kawano T, Nagai K and Inoue H: Clinicopathologic analysis of lymph node metastasis in surgically resected superficial cancer of the thoracic esophagus. Dis Esophagus 13: 125-129, 2000.
20. Araki K, Ohno S, Egashira A, Saeki H, Kawaguchi H and Sugimachi K: Pathologic features of superficial esophageal squamous cell carcinoma with lymph node and distal metastasis. Cancer 94: 570-575, 2002.
21. Eguchi T, Nakanishi Y, Shimoda T, et al: Histopathological criteria for additional treatment after endoscopic mucosal resection for esophageal cancer: analysis of 464 surgically resected cases. Mod Pathol 19: 475-480, 2006.
22. Shimada H, Nabeya Y, Matsubara H, et al: Prediction of lymph node status in patients with superficial esophageal carcinoma: analysis of 160 surgically resected cancers. Am J Surg 191: 250-254, 2006.
23. Han U, Can OI, Han S, Kayhan B and Onal BU: Expressions of p53, VEGF C, p21: could they be used in preoperative evaluation of lymph node metastasis of esophageal squamous cell carcinoma? Dis Esophagus 20: 379-385, 2007.
24. Li JQ, Miki H, Ohmori M, Wu F and Funamoto Y: Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma. Hum Pathol 32: 945-953, 2001.